Dual-target proteasome drugs for triple negative breast cancer
Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancer
Developing new drugs that block two parts of the cell's protein‑cleanup machinery to help people with triple negative breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11247455 on NIH RePORTER |
What this research studies
Researchers are designing drugs that simultaneously block two proteasome subunits (called beta5 and beta2) that cancer cells use to survive. Lab tests will use cancer cells and animal models to see whether blocking both parts prevents tumor cells from escaping treatment and reduces resistance. The team will compare effects to existing proteasome drugs and look for signs of lower toxicities such as nerve or heart side effects. If the lab results are promising, this work could support future early‑phase clinical trials at the sponsoring center.
Who could benefit from this research
Good fit: People with triple negative breast cancer, especially those with advanced or treatment‑resistant disease, would be the likely candidates if and when clinical testing begins.
Not a fit: People with other breast cancer subtypes (hormone receptor or HER2 positive) or those needing immediate standard therapy are unlikely to benefit from this preclinical program now.
Why it matters
Potential benefit: This could lead to a new treatment option for triple negative breast cancer that is more effective against resistant tumors and may have fewer severe side effects.
How similar studies have performed: Proteasome inhibitors have transformed care for blood cancers like multiple myeloma but have shown little benefit in solid tumors so far, and targeting both beta5 and beta2 is a newer approach with encouraging preclinical results.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Lin, Gang — Weill Medical Coll of Cornell Univ
- Study coordinator: Lin, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.